ASLAN Pharmaceuticals today announced the enrolment of the first subject in a phase 1 study investigating ASLAN004 as a therapeutic antibody for atopic dermatitis.
For more information, please refer to the English or Chinese press release.
The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.
ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.
Read about our latest product developments and partnerships, industry advances and events.